Eltrombopag enhances platelet response in chronic ITP patients

06/10/2009 | Doctor's Guide

A Phase III trial showed that eltrombopag improved overall platelet responses compared with a placebo in patients with chronic idiopathic thrombocytopenic purpura [who were either splenectomized or not]. "This eltrombopag treatment not only provides results in the short term, but also provides sustained and durable responses," a researcher said.

View Full Article in:

Doctor's Guide

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA